mRNA Vaccine Plus Pembrolizumab Delays Recurrence in High-Risk Melanoma in Phase 3 Trial

Results from a phase 3 clinical trial showed that an mRNA vaccine combined with pembrolizumab significantly delayed postoperative recurrence and metastasis in patients with high-risk melanoma. The trial enrolled postoperative patients and was designed to evaluate the combination therapy's inhibitory effect on tumor recurrence and metastasis. The results demonstrated that the combination regimen had a clear effect in delaying disease progression. The trial data provide new evidence-based support for the field of cancer treatment, although the therapy's broader applicability and long-term efficacy will require confirmation through further research.